FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2092152920> ?p ?o ?g. }

• W2092152920 endingPage "388" @default.
• W2092152920 startingPage "385" @default.
• W2092152920 abstract "Tumour cells with defective mitochondria are found to use glutamine-dependent reductive carboxylation, rather than oxidative metabolism, as the major pathway of citrate and lipid formation. Oxidative metabolism of glucose has long been considered to be the major provider of carbon for lipid synthesis in animal cells. Two papers in this issue of Nature demonstrate that reductive carboxylation of glutamine is an alternative. Metallo et al. show that various normal and cancerous human cell lines proliferating in hypoxic conditions produce the acetyl-coenzyme A required as a precursor for fatty acid synthesis by the reductive metabolism of glutamine-derived α-ketoglutarate through a pathway requiring isocitrate dehydrogenase 1. Mullen et al. show that tumour cells with defective mitochondria use glutamine-dependent reductive carboxylation as the major pathway of citrate formation. As well as adding a new dimension to our understanding of cell carbohydrate metabolism, this work suggests that there may be potential therapeutic targets along the reductive carboxylation and glutamine catabolic pathways that could prevent hypoxic tumour growth. Mitochondrial metabolism provides precursors to build macromolecules in growing cancer cells1,2. In normally functioning tumour cell mitochondria, oxidative metabolism of glucose- and glutamine-derived carbon produces citrate and acetyl-coenzyme A for lipid synthesis, which is required for tumorigenesis3. Yet some tumours harbour mutations in the citric acid cycle (CAC) or electron transport chain (ETC) that disable normal oxidative mitochondrial function4,5,6,7, and it is unknown how cells from such tumours generate precursors for macromolecular synthesis. Here we show that tumour cells with defective mitochondria use glutamine-dependent reductive carboxylation rather than oxidative metabolism as the major pathway of citrate formation. This pathway uses mitochondrial and cytosolic isoforms of NADP+/NADPH-dependent isocitrate dehydrogenase, and subsequent metabolism of glutamine-derived citrate provides both the acetyl-coenzyme A for lipid synthesis and the four-carbon intermediates needed to produce the remaining CAC metabolites and related macromolecular precursors. This reductive, glutamine-dependent pathway is the dominant mode of metabolism in rapidly growing malignant cells containing mutations in complex I or complex III of the ETC, in patient-derived renal carcinoma cells with mutations in fumarate hydratase, and in cells with normal mitochondria subjected to acute pharmacological ETC inhibition. Our findings reveal the novel induction of a versatile glutamine-dependent pathway that reverses many of the reactions of the canonical CAC, supports tumour cell growth, and explains how cells generate pools of CAC intermediates in the face of impaired mitochondrial metabolism." @default.
• W2092152920 created "2016-06-24" @default.
• W2092152920 creator A5003771525 @default.
• W2092152920 creator A5004211801 @default.
• W2092152920 creator A5013924501 @default.
• W2092152920 creator A5026571379 @default.
• W2092152920 creator A5033345950 @default.
• W2092152920 creator A5046518034 @default.
• W2092152920 creator A5062930646 @default.
• W2092152920 creator A5063101522 @default.
• W2092152920 creator A5087074836 @default.
• W2092152920 creator A5087215984 @default.
• W2092152920 date "2011-11-20" @default.
• W2092152920 modified "2023-10-09" @default.
• W2092152920 title "Reductive carboxylation supports growth in tumour cells with defective mitochondria" @default.
• W2092152920 cites W1483212110 @default.
• W2092152920 cites W1523008440 @default.
• W2092152920 cites W1967291345 @default.
• W2092152920 cites W1982330633 @default.
• W2092152920 cites W1987695736 @default.
• W2092152920 cites W1995675594 @default.
• W2092152920 cites W1996365670 @default.
• W2092152920 cites W1999434929 @default.
• W2092152920 cites W2018504915 @default.
• W2092152920 cites W2021793290 @default.
• W2092152920 cites W2028117213 @default.
• W2092152920 cites W2028449239 @default.
• W2092152920 cites W2033471108 @default.
• W2092152920 cites W2037573325 @default.
• W2092152920 cites W2039212784 @default.
• W2092152920 cites W2043034889 @default.
• W2092152920 cites W2044565982 @default.
• W2092152920 cites W2059144115 @default.
• W2092152920 cites W2060592426 @default.
• W2092152920 cites W2074873270 @default.
• W2092152920 cites W2093361250 @default.
• W2092152920 cites W2097259163 @default.
• W2092152920 cites W2104457605 @default.
• W2092152920 cites W2108648814 @default.
• W2092152920 cites W2126511952 @default.
• W2092152920 cites W2160159824 @default.
• W2092152920 doi "https://doi.org/10.1038/nature10642" @default.
• W2092152920 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3262117" @default.
• W2092152920 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22101431" @default.
• W2092152920 hasPublicationYear "2011" @default.
• W2092152920 type Work @default.
• W2092152920 sameAs 2092152920 @default.
• W2092152920 citedByCount "1051" @default.
• W2092152920 countsByYear W20921529202012 @default.
• W2092152920 countsByYear W20921529202013 @default.
• W2092152920 countsByYear W20921529202014 @default.
• W2092152920 countsByYear W20921529202015 @default.
• W2092152920 countsByYear W20921529202016 @default.
• W2092152920 countsByYear W20921529202017 @default.
• W2092152920 countsByYear W20921529202018 @default.
• W2092152920 countsByYear W20921529202019 @default.
• W2092152920 countsByYear W20921529202020 @default.
• W2092152920 countsByYear W20921529202021 @default.
• W2092152920 countsByYear W20921529202022 @default.
• W2092152920 countsByYear W20921529202023 @default.
• W2092152920 crossrefType "journal-article" @default.
• W2092152920 hasAuthorship W2092152920A5003771525 @default.
• W2092152920 hasAuthorship W2092152920A5004211801 @default.
• W2092152920 hasAuthorship W2092152920A5013924501 @default.
• W2092152920 hasAuthorship W2092152920A5026571379 @default.
• W2092152920 hasAuthorship W2092152920A5033345950 @default.
• W2092152920 hasAuthorship W2092152920A5046518034 @default.
• W2092152920 hasAuthorship W2092152920A5062930646 @default.
• W2092152920 hasAuthorship W2092152920A5063101522 @default.
• W2092152920 hasAuthorship W2092152920A5087074836 @default.
• W2092152920 hasAuthorship W2092152920A5087215984 @default.
• W2092152920 hasBestOaLocation W20921529202 @default.
• W2092152920 hasConcept C161790260 @default.
• W2092152920 hasConcept C165135838 @default.
• W2092152920 hasConcept C185592680 @default.
• W2092152920 hasConcept C24428623 @default.
• W2092152920 hasConcept C2779349466 @default.
• W2092152920 hasConcept C28859421 @default.
• W2092152920 hasConcept C4733338 @default.
• W2092152920 hasConcept C515207424 @default.
• W2092152920 hasConcept C55493867 @default.
• W2092152920 hasConcept C57600042 @default.
• W2092152920 hasConcept C62231903 @default.
• W2092152920 hasConcept C86803240 @default.
• W2092152920 hasConceptScore W2092152920C161790260 @default.
• W2092152920 hasConceptScore W2092152920C165135838 @default.
• W2092152920 hasConceptScore W2092152920C185592680 @default.
• W2092152920 hasConceptScore W2092152920C24428623 @default.
• W2092152920 hasConceptScore W2092152920C2779349466 @default.
• W2092152920 hasConceptScore W2092152920C28859421 @default.
• W2092152920 hasConceptScore W2092152920C4733338 @default.
• W2092152920 hasConceptScore W2092152920C515207424 @default.
• W2092152920 hasConceptScore W2092152920C55493867 @default.
• W2092152920 hasConceptScore W2092152920C57600042 @default.
• W2092152920 hasConceptScore W2092152920C62231903 @default.
• W2092152920 hasConceptScore W2092152920C86803240 @default.
• W2092152920 hasIssue "7381" @default.
• W2092152920 hasLocation W20921529201 @default.

• next